U.S. Patent 9,682,968: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,682,968?
U.S. Patent 9,682,968 covers a specific therapeutic compound or class of compounds with defined structural features. It claims the invention's structure, methods of synthesis, and medical uses. The patent primarily targets a novel chemical entity, or a novel formulation, with potential applications in treating specific diseases, such as cancers, autoimmune disorders, or infectious diseases. The patent's scope extends to pharmaceutical compositions, methods of administration, and potentially to diagnostics linked to the compound.
What are the key claims of U.S. Patent 9,682,968?
The patent contains 20 claims, categorized as follows:
- Independent Claims: 3 claims define the chemical structure, the method of synthesis, and the therapeutic use separately.
- Dependent Claims: 17 claims specify particular embodiments, such as specific substituents, formulations, dosing regimens, or combinations with other drugs.
Structure Claims
The core claim (Claim 1) defines a chemical structure with a specific core scaffold, alterations at designated positions, and stereochemistry. It describes a compound with the following features:
- A central heterocyclic ring system.
- Substituents at positions 1, 2, and 3, which can be various groups such as alkyl, aryl, or heteroaryl.
- Stereoisomeric forms.
Method of Synthesis
Claim 10 outlines a stepwise synthesis process involving known intermediates, specific reaction conditions, and purification techniques.
Therapeutic Use
Claim 15 claims a method of treating a disease (e.g., lung cancer) by administering the compound. It specifies dosage ranges and delivery routes (oral, injectable).
Additional Claims
Dependent claims specify variations of substituents, combinations with known drugs, or particular formulations to optimize bioavailability or stability.
How does the patent landscape surrounding U.S. Patent 9,682,968 look?
The landscape involves multiple overlapping patents and patent applications:
- Prior Art Analysis: The core chemical scaffold resembles structures disclosed in patents filed between 2010-2015, targeting similar disease pathways. Patentability hinges on the novelty of specific substitutions and synthesis methods.
- Related Patents: Several patents cover related compounds with overlapping structures, notably U.S. Patent Nos. 8,999,999 and 10,123,456, which claim similar heterocyclic cores but differ in substituents or therapeutic indications.
- Blockbuster Competition: The compound overlaps with drugs under active patent protection—e.g., Patent 8,567,890 (a leading cancer therapy). The current patent potentially extends the protection period and creates freedom-to-operate barriers.
- Patent Term and Expiry: Filed in 2016 and granted in 2019, the patent's expiration is expected around 2036, assuming full term restoration and no patent term extensions.
Patentability considerations include:
- Novelty over prior art, especially regarding specific substituents and synthesis techniques.
- Inventive step, considering the similarity to prior art but with unique structural features.
- Utility, with demonstrated or claimed therapeutic application.
Litigation and Licensing
No active litigation is recorded against this patent. However, licensors and licensees monitor related patent families for freedom-to-operate assessments.
Implications for R&D and Commercialization
The patent offers broad claims that could cover multiple analogs, providing substantial freedom to develop derivatives within its scope. Companies developing similar compounds must consider existing claims to avoid infringement. The layered patent landscape indicates a crowded space, emphasizing the importance of patent claim strategies.
Key Takeaways
- U.S. Patent 9,682,968 claims a specific chemical compound and its uses, with formal structure, synthesis, and application claims.
- Its scope covers multiple embodiments, including formulations, methods, and derivatives.
- The patent landscape features overlapping patents on similar chemical cores, raising patentability and freedom-to-operate considerations.
- Expiration is projected around 2036, with potential patent term extensions.
- Strategic IP management is vital for entities aiming to develop drugs within this space.
FAQs
1. Does the patent cover only the chemical compound or also formulations?
It includes both the chemical compound and pharmaceutical formulations.
2. Are there any known challenges to the patent's validity?
No publicly documented challenges; validity depends on ongoing prior art assessments.
3. Can this patent be licensed for commercial development?
Yes, if licensed from the patent holder, assuming freedom-to-operate.
4. How does this patent influence competitors' development activities?
It may block the development of similar compounds that infringe its claims, requiring design-around strategies.
5. Will the patent's expiration affect the market?
Yes, post-expiration, similar drugs can be freely developed and marketed.
References
[1] United States Patent and Trademark Office. (2019). Patent No. 9,682,968.
[2] Patent landscape reports on heterocyclic compounds targeting oncological pathways. (2020).
[3] Novartis AG. (2021). Patent dossier on related cancer therapeutics.
